GENINCODE PLC LS -01

Research GENINCODE PLC LS -01 (9PL) on Bullrun: market cap EUR 5.65M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is EUR 5.65M.

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025GBP 3.08M-GBP 5.71M-GBP 4.17M58.6%-0.02GBP 827.00KGBP 146.00KGBP 124.00K
FY2024GBP 2.70M-GBP 4.43M-GBP 5.22M52.8%-0.03GBP 1.11MGBP 234.00KGBP 1.13M
FY2023GBP 2.16M-GBP 7.02M-GBP 7.54M47.3%-0.07GBP 2.48MGBP 299.00KGBP 1.29M
FY2022GBP 1.43M-GBP 5.56M-GBP 4.57M44.2%-0.06GBP 9.73MGBP 354.00KGBP 7.90M
FY2021GBP 1.15M-GBP 4.14M-GBP 3.24M51.4%-0.08GBP 14.55MGBP 0GBP 13.72M

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-27EUR 5.65Mn/an/a0

Dividend history

Latest trailing dividend snapshot: annual dividend/share 0 EUR.

About GENINCODE PLC LS -01

GENinCode Plc engages in the development and commercialization of clinical genetic tests for predictive analysis of risk to a patient's health based on genes in the United Kingdom, Spain, Italy, the United States, Germany, and internationally. The company offers CARDIO inCode Score, a genetic test to evaluate the risk of coronary heart disease; LIPID inCode, a genetic test for the diagnosis of familial hypercholesterolemia with further coronary risk stratification of the patient;

Related stock research

Other Healthcare stocks

Frequently asked questions

What is GENINCODE PLC LS -01's market cap?

GENINCODE PLC LS -01's market capitalization is EUR 5.65M.

What does GENINCODE PLC LS -01 do?

GENinCode Plc engages in the development and commercialization of clinical genetic tests for predictive analysis of risk to a patient's health based on genes in the United Kingdom, Spain, Italy, the United States, Germany, and internationally.